Evidence map›Paper›PMID 35992865›Full record

ArticleFrontiers in oncology2022

A nomogram to predict survival probability of gastric cancer patients undergoing radical surgery and adjuvant chemotherapy.

Ling Ma, Guosheng Chen, Deqiang Wang, Kai Zhang, Fengjiao Zhao, Jie Tang, Jianyi Zhao, Oluf Dimitri Røe, Shaohua He, Dongcheng Liao and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 5 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 5 syntheses or guidelines pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 2 countries.

Ling MaDepartment of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Guosheng ChenPancreatic Center and Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Deqiang WangThe Cancer Therapy Center, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Kai ZhangPancreatic Center and Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Fengjiao ZhaoDepartment of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Jie TangDepartment of Oncology, Liyang People's Hospital, Liyang, China.
Jianyi ZhaoDepartment of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Oluf Dimitri RøeDepartment of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Shaohua HeThe Key Laboratory of Cancer Prevention and Treatment, Second People's Hospital of Huaihua City, Huaihua, China.
Dongcheng LiaoThe Key Laboratory of Cancer Prevention and Treatment, Second People's Hospital of Huaihua City, Huaihua, China.
Yanhong GuDepartment of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Min TaoDepartment of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Yongqian ShuDepartment of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Wei LiDepartment of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Xiaofeng ChenDepartment of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Nanjing Medical University · CNSecond People’s Hospital of Huai’an · CNSoochow University · CNJiangsu Province Hospital · CNJiangsu University · CNNorwegian University of Science and Technology · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastric cancer (GC) is the third-leading cause of cancer mortality worldwide. The aim of this study was to develop a nomogram that estimates 1-year, 3-year, and 5-year survival probability of GC patients after D2 gastrectomy combined with adjuvant chemotherapy. The results showed that median age is 58 (range: 18-85) years in the training cohort and 59 (range: 32-85) years in the validation cohort. On multivariate analysis, four factors were found to be significantly associated with worse overall survival (OS): late TNM stage, positive resection margin, preoperative carcinoembryonic antigen (CEA) level, and single chemotherapy regimens compared with multiple chemotherapy regimens. All of these findings were validated in the validation cohort. Furthermore, the four factors were included in the final nomogram for the prediction of 1-year, 3-year, and 5-year survival probability, with accurate calibration and reasonable discrimination (C-index = 0.676 for training cohort, and C-index = 0.664 for validation cohort). The AUC values analyzed by the ROC analysis demonstrated a good predictive accuracy of the nomogram for OS (1-year, 3-year, and 5-year OS were 94.43%, 77.42%, and 73.03% in the training cohort, respectively; 96.95%, 81.54%, and 73.41% in the validation cohort, respectively). In conclusion, the proposed nomogram may be used to objectively and accurately predict survival probability of GC patients in a multi-institutional clinical setting.

Indexed as

chemotherapygastric cancernomogramoverall survivalprognostic scoring system

Identifiers

PMID35992865
PMCPMC9389342
OpenAlexW4289939566

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.